BACKGROUND: Obesity management requires understanding the mortality risks associated with different adiposity measures. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 5,805 adults with body mass index (BMI) ≥18.5 kg/m(2) and stages 1-4 chronic kidney disease, defined as a spot urine albumin-creatinine ratio ≥30 mg/g and/or estimated glomerular filtration rate <60 mL/min/1.73 m(2), enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. PREDICTOR: BMI categorized as 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, and ≥40 kg/m(2) and waist circumference categorized as <80, 80-87.9, 88-97.9, 98-107.9, and ≥108 cm in women and <94, 94-101.9, 102-111.9, 112-121.9, and ≥122 cm in men. OUTCOMES: All-cause mortality. MEASUREMENTS: BMI and waist circumference were measured using a standardized protocol during the home visit. RESULTS: 686 (11.8%) deaths occurred during a median follow-up of 4 years. Compared with the referent BMI category of 25-29.9 kg/m(2), HRs for mortality were 1.27 (95% CI, 0.96-1.69) for BMI <25 kg/m(2) and 0.84 (95% CI, 0.62-1.13), 0.81 (95% CI, 0.52-1.26), and 0.95 (95% CI, 0.54-1.65) for BMI categories 30-34.9, 35-39.9, and ≥40 kg/m(2) after adjustment for covariates including waist circumference, respectively. In contrast, after adjustment for covariates including BMI, higher mortality rates were noted for all waist circumference categories compared with the referent (<80 cm in women and <94 cm in men), with HRs of 1.04 (95% CI, 0.77-1.41) for waist circumference of 80-87.9 cm in women and 94-101.9 cm in men, 1.29 (95% CI, 0.92-1.81) for waist circumference of 88-97.9 cm in women and 102-111.9 cm in men, 1.72 (95% CI, 1.12-2.62) for waist circumference of 98-107.9 cm in women and 112-121.9 cm in men, and 2.09 (95% CI, 1.26-3.46) for waist circumference ≥108 cm in women and ≥122 cm in men. LIMITATIONS: BMI and waist circumference measured at baseline only. CONCLUSIONS: Waist circumference should be considered in conjunction with BMI when assessing mortality risk associated with obesity in adults with chronic kidney disease.
BACKGROUND:Obesity management requires understanding the mortality risks associated with different adiposity measures. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 5,805 adults with body mass index (BMI) ≥18.5 kg/m(2) and stages 1-4 chronic kidney disease, defined as a spot urine albumin-creatinine ratio ≥30 mg/g and/or estimated glomerular filtration rate <60 mL/min/1.73 m(2), enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. PREDICTOR: BMI categorized as 18.5-24.9, 25.0-29.9, 30.0-34.9, 35.0-39.9, and ≥40 kg/m(2) and waist circumference categorized as <80, 80-87.9, 88-97.9, 98-107.9, and ≥108 cm in women and <94, 94-101.9, 102-111.9, 112-121.9, and ≥122 cm in men. OUTCOMES: All-cause mortality. MEASUREMENTS: BMI and waist circumference were measured using a standardized protocol during the home visit. RESULTS: 686 (11.8%) deaths occurred during a median follow-up of 4 years. Compared with the referent BMI category of 25-29.9 kg/m(2), HRs for mortality were 1.27 (95% CI, 0.96-1.69) for BMI <25 kg/m(2) and 0.84 (95% CI, 0.62-1.13), 0.81 (95% CI, 0.52-1.26), and 0.95 (95% CI, 0.54-1.65) for BMI categories 30-34.9, 35-39.9, and ≥40 kg/m(2) after adjustment for covariates including waist circumference, respectively. In contrast, after adjustment for covariates including BMI, higher mortality rates were noted for all waist circumference categories compared with the referent (<80 cm in women and <94 cm in men), with HRs of 1.04 (95% CI, 0.77-1.41) for waist circumference of 80-87.9 cm in women and 94-101.9 cm in men, 1.29 (95% CI, 0.92-1.81) for waist circumference of 88-97.9 cm in women and 102-111.9 cm in men, 1.72 (95% CI, 1.12-2.62) for waist circumference of 98-107.9 cm in women and 112-121.9 cm in men, and 2.09 (95% CI, 1.26-3.46) for waist circumference ≥108 cm in women and ≥122 cm in men. LIMITATIONS: BMI and waist circumference measured at baseline only. CONCLUSIONS: Waist circumference should be considered in conjunction with BMI when assessing mortality risk associated with obesity in adults with chronic kidney disease.
Authors: David G Warnock; William McClellan; Leslie A McClure; Britt Newsome; Ruth C Campbell; Paul Audhya; Mary Cushman; Virginia J Howard; George Howard Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: David G Warnock; Paul Muntner; Peter A McCullough; Xiao Zhang; Leslie A McClure; Neil Zakai; Mary Cushman; Britt B Newsome; Reshma Kewalramani; Michael W Steffes; George Howard; William M McClellan Journal: Am J Kidney Dis Date: 2010-08-08 Impact factor: 8.860
Authors: Janne Bigaard; Anne Tjønneland; Birthe Lykke Thomsen; Kim Overvad; Berit Lilienthal Heitmann; Thorkild I A Sørensen Journal: Obes Res Date: 2003-07
Authors: Lynae J Hanks; Rikki M Tanner; Paul Muntner; Holly Kramer; William M McClellan; David G Warnock; Suzanne E Judd; Orlando M Gutiérrez Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Holly Kramer; Orlando M Gutiérrez; Suzanne E Judd; Paul Muntner; David G Warnock; Rikki M Tanner; Bhupesh Panwar; David A Shoham; William McClellan Journal: Am J Kidney Dis Date: 2015-07-15 Impact factor: 8.860
Authors: Seyed-Foad Ahmadi; Golara Zahmatkesh; Emad Ahmadi; Elani Streja; Connie M Rhee; Daniel L Gillen; Luca De Nicola; Roberto Minutolo; Ana C Ricardo; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Cardiorenal Med Date: 2015-10-16 Impact factor: 2.041
Authors: Ana C Ricardo; Magdalena Madero; Wei Yang; Cheryl Anderson; Matthew Menezes; Michael J Fischer; Mary Turyk; Martha L Daviglus; James P Lash Journal: Clin J Am Soc Nephrol Date: 2013-03-21 Impact factor: 8.237
Authors: S Popa; M Moţa; A Popa; E Moţa; C Serafinceanu; C Guja; D Catrinoiu; N Hâncu; R Lichiardopol; C Bala; A Popa; G Roman; G Radulian; R Timar; B Mihai Journal: J Endocrinol Invest Date: 2016-04-28 Impact factor: 4.256